quinoxalines has been researched along with Behavior Disorders in 33 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (36.36) | 29.6817 |
| 2010's | 21 (63.64) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Back, D; Belperio, P; Bondin, M; Crown, E; Marra, F; Mensa, FJ; Negro, F; Park, C; Pinsky, B; Talal, AH; Zhang, Z | 1 |
| Hviid, A; Pasternak, B; Svanström, H | 1 |
| Buggy, Y; Cornelius, V; Fogg, C; Kasliwal, R; Layton, D; Shakir, SA | 1 |
| Gibbons, RD; Mann, JJ | 1 |
| Beard, JD; Davis, RE; Hendrick, JP; Lee, T; Li, P; Mates, S; Peng, Y; Robichaud, AJ; Snyder, GL; Tomesch, J; Vanover, KE; Wennogle, LP; Yao, W; Zhang, Q; Zhu, H | 1 |
| Aitken, D; Clyde, M; Corran, B; Els, C; Pipe, A; Reid, RD; Tulloch, H | 1 |
| Rausch, R | 1 |
| Gunnell, D; Higgins, JP; Knipe, DW; Martin, RM; Thomas, KH | 1 |
| Harrison-Woolrych, M | 1 |
| Fazel, S; Gumpert, CH; Lichtenstein, P; Molero, Y; Zetterqvist, J | 1 |
| Cahill, K; Lancaster, T | 1 |
| Nadeem, SS; Pirmoradi, P; Roshan, S | 1 |
| Boyd, JW; Lasser, KE | 1 |
| Tavares, AR | 1 |
| Balvanz, TM; Magallon, HE; Mambourg, SE; Pham, RH; Purvis, TL | 1 |
| Dupont, P; Gillet, C; Guerin, M; Guillaumin, C; Kalamarides, S; Larinier, E; Meignan, C; Moreau, A; Perriot, J | 1 |
| Cantrell, FL; Clark, AK; Clark, RF; Kreshak, AA; Ly, BT | 1 |
| Richins, C | 1 |
| Burke, MV; Ebbert, JO; Hays, J; Wyatt, KD; Zirakzadeh, A | 1 |
| Mambourg, SE; Nelson, LA; Purvis, TL | 1 |
| Davies, S; Flammer, M; Hughes, J; Russ, C; Tonstad, S | 1 |
| Catz, SL; Deprey, M; Jack, L; Javitz, H; McAfee, T; McClure, JB; Richards, J; Swan, GE; Zbikowski, SM | 1 |
| Furberg, CD; Glenmullen, J; Moore, TJ | 1 |
| Ashton, J; Harrison-Woolrych, M | 1 |
| Jones, DL; Rankin, KV | 1 |
| Coster, TS; Graham, DJ; Meyer, TE; Moeny, D; Mosholder, AD; Ouellet-Hellstrom, RP; Taylor, LG; Williams, JR; Xie, S | 1 |
| Ahmed, AI; Ali, AN; Burger, DM; Härmark, LV; Kramers, C; Verhoeven, WM | 1 |
| Arnsten, JH; Bernstein, SL; Nahvi, S; Richter, KP; Wu, B | 1 |
| Dervaux, A; Kanit, M; Laqueille, X | 1 |
| Milbrandt, A; Ratcliffe, M; Smith, R; Spirling, LI; Stapleton, JA; Sutherland, G; Watson, L | 1 |
| Kuehn, BM | 1 |
| Perno Goldie, M | 1 |
5 review(s) available for quinoxalines and Behavior Disorders
| Article | Year |
|---|---|
Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis.
Topics: Aggression; Benzazepines; Depression; Humans; Mental Disorders; Quinoxalines; Risk Factors; Sleep Wake Disorders; Suicide; Suicide, Attempted; Tobacco Use Cessation Devices; Varenicline | 2015 |
Clinical utility of varenicline for smokers with medical and psychiatric comorbidity.
Topics: Benzazepines; Cardiovascular Diseases; Drug Labeling; Humans; Mental Disorders; Nicotinic Agonists; Pulmonary Disease, Chronic Obstructive; Quinoxalines; Smoking; Smoking Cessation; Tobacco Use Disorder; Treatment Outcome; Varenicline | 2009 |
Varenicline use in patients with mental illness: an update of the evidence.
Topics: Benzazepines; Evidence-Based Medicine; Humans; Limbic System; Mental Disorders; Mood Disorders; Patient Education as Topic; Quinoxalines; Smoking; Smoking Cessation; Suicide; Treatment Outcome; Varenicline | 2010 |
Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis.
Topics: Adolescent; Adult; Aged; Benzazepines; Double-Blind Method; Female; Humans; Incidence; Male; Mental Disorders; Middle Aged; Nicotinic Agonists; Placebos; Quinoxalines; Randomized Controlled Trials as Topic; Risk; Sleep Wake Disorders; Smoking Cessation; Varenicline | 2010 |
Neuropsychiatric adverse events of varenicline: a systematic review of published reports.
Topics: Adult; Aged; Benzazepines; Comorbidity; Female; Humans; Male; Mental Disorders; Middle Aged; Nicotinic Agonists; Quinoxalines; Risk Assessment; Risk Factors; Smoking Cessation; Smoking Prevention; Time Factors; Varenicline; Young Adult | 2013 |
2 trial(s) available for quinoxalines and Behavior Disorders
| Article | Year |
|---|---|
Flexible and extended dosing of nicotine replacement therapy or varenicline in comparison to fixed dose nicotine replacement therapy for smoking cessation: rationale, methods and participant characteristics of the FLEX trial.
Topics: Adult; Benzazepines; Female; Humans; Male; Mental Disorders; Middle Aged; Nicotinic Agonists; Quinoxalines; Research Design; Smoking Cessation; Socioeconomic Factors; Substance Withdrawal Syndrome; Tobacco Use Cessation Devices; Varenicline | 2014 |
Smoking outcome by psychiatric history after behavioral and varenicline treatment.
Topics: Adult; Behavior Therapy; Benzazepines; Combined Modality Therapy; Directive Counseling; Female; Follow-Up Studies; Humans; Male; Mental Disorders; Middle Aged; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Treatment Outcome; Varenicline | 2010 |
26 other study(ies) available for quinoxalines and Behavior Disorders
| Article | Year |
|---|---|
Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis.
Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antidepressive Agents; Antiviral Agents; Benzimidazoles; Cyclopropanes; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Mental Disorders; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Sustained Virologic Response; Treatment Adherence and Compliance; Young Adult | 2019 |
Use of varenicline versus bupropion and risk of psychiatric adverse events.
Topics: Adult; Benzazepines; Bupropion; Denmark; Dopamine Uptake Inhibitors; Female; Humans; Male; Mental Disorders; Middle Aged; Nicotinic Agonists; Proportional Hazards Models; Quinoxalines; Risk Factors; Smoking Cessation; Smoking Prevention; Treatment Outcome; Varenicline | 2013 |
Neuropsychiatric events with varenicline: a modified prescription-event monitoring study in general practice in England.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Benzazepines; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; England; Female; General Practice; Humans; Incidence; Male; Mental Disorders; Middle Aged; Nicotinic Agonists; Product Surveillance, Postmarketing; Quinoxalines; Smoking Cessation; Varenicline | 2013 |
Varenicline, smoking cessation, and neuropsychiatric adverse events.
Topics: Adult; Aggression; Akathisia, Drug-Induced; Benzazepines; Bupropion; Depression; Female; Humans; Male; Mental Disorders; Nausea; Observational Studies as Topic; Psychomotor Agitation; Quinoxalines; Randomized Controlled Trials as Topic; Risk Factors; Smoking Cessation; Suicidal Ideation; Suicide, Attempted; Tobacco Use Cessation Devices; Treatment Outcome; Varenicline | 2013 |
Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders.
Topics: Adrenergic Uptake Inhibitors; Animals; Behavior, Animal; Biological Availability; Drug Discovery; Electroshock; Indicators and Reagents; Male; Mental Disorders; Nervous System Diseases; Quinoxalines; Quipazine; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Recombinant Proteins; Schizophrenia; Serotonin Antagonists; Serotonin Plasma Membrane Transport Proteins; Structure-Activity Relationship | 2014 |
[Abstinence rates among varenicline are highest].
Topics: Benzazepines; Bupropion; Humans; Mental Disorders; Quinoxalines; Smoking Cessation; Treatment Outcome; Varenicline | 2014 |
Mental health effects of varenicline.
Topics: Benzazepines; Humans; Mental Disorders; Quinoxalines; Sleep Wake Disorders; Tobacco Use Cessation Devices; Varenicline | 2015 |
Varenicline and risk of psychiatric conditions, suicidal behaviour, criminal offending, and transport accidents and offences: population based cohort study.
Topics: Accidents, Traffic; Adolescent; Adult; Aged; Benzazepines; Cohort Studies; Crime; Epidemiologic Methods; Female; Humans; Male; Mental Disorders; Middle Aged; Nicotinic Agonists; Quinoxalines; Smoking; Smoking Cessation; Smoking Prevention; Substance Withdrawal Syndrome; Suicide; Tobacco Use Cessation Devices; Varenicline; Young Adult | 2015 |
ACP Journal Club. Review: Varenicline does not differ from placebo for adverse neuropsychiatric events.
Topics: Benzazepines; Humans; Mental Disorders; Quinoxalines; Sleep Wake Disorders; Tobacco Use Cessation Devices | 2015 |
Varenicline (Chantix) warnings: risk versus benefit.
Topics: Benzazepines; Drug Partial Agonism; Humans; Mental Disorders; Nicotinic Agonists; Quinoxalines; Risk Assessment; Risk Factors; Smoking Cessation; Tobacco Use Disorder; Treatment Outcome; Varenicline | 2008 |
Neuropsychiatric disturbance after initiation of varenicline in a patient with a history of alcohol abuse and major depression.
Topics: Adult; Alcoholism; Benzazepines; Depressive Disorder, Major; Humans; Male; Mental Disorders; Nervous System Diseases; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Tobacco Use Disorder; Varenicline | 2008 |
Varenicline and smokers with mental illnesses.
Topics: Benzazepines; Humans; Mental Disorders; Patient Selection; Quinoxalines; Randomized Controlled Trials as Topic; Risk Factors; Smoking Cessation; Varenicline | 2008 |
Varenicline for tobacco dependence.
Topics: Benzazepines; Humans; Mental Disorders; Nicotinic Agonists; Quinoxalines; Smoking; Suicide; Tobacco Use Disorder; Varenicline | 2009 |
Safety and effectiveness of varenicline in a veteran population with a high prevalence of mental illness.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Benzazepines; Diagnosis, Dual (Psychiatry); Female; Humans; Male; Mental Disorders; Middle Aged; Nicotinic Agonists; Quinoxalines; Retrospective Studies; Sex Factors; Smoking Cessation; Tobacco Use Disorder; Varenicline; Veterans | 2009 |
[Tolerability profile of varenicline in current medical practice].
Topics: Adult; Benzazepines; Female; France; Gastrointestinal Diseases; Humans; Male; Mental Disorders; Metabolic Diseases; Nervous System Diseases; Nicotinic Agonists; Quinoxalines; Retrospective Studies; Skin Diseases; Smoking; Varenicline | 2010 |
A retrospective poison center review of varenicline-exposed patients.
Topics: Adolescent; Adult; Benzazepines; Child, Preschool; Databases, Factual; Female; Follow-Up Studies; Gastrointestinal Diseases; Humans; Infant; Male; Medication Errors; Mental Disorders; Nicotinic Agonists; Poison Control Centers; Quinoxalines; Retrospective Studies; Smoking Cessation; Varenicline | 2009 |
Regulation of smoking cessation drugs by the Food and Drug Administration.
Topics: Benzazepines; Clinical Trials as Topic; Drug Approval; Drug Interactions; Government Regulation; Humans; Mental Disorders; Nicotinic Agonists; Product Surveillance, Postmarketing; Psychotropic Drugs; Quinoxalines; Smoking; Smoking Cessation; United States; United States Food and Drug Administration; Varenicline | 2009 |
Thoughts and acts of aggression/violence toward others reported in association with varenicline.
Topics: Adult; Aggression; Benzazepines; Female; Humans; Male; Mental Disorders; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Thinking; Varenicline; Violence | 2010 |
Psychiatric adverse events associated with varenicline: an intensive postmarketing prospective cohort study in New Zealand.
Topics: Adult; Aged; Aged, 80 and over; Benzazepines; Cohort Studies; Female; Follow-Up Studies; Humans; Male; Mental Disorders; Middle Aged; New Zealand; Nicotinic Agonists; Product Surveillance, Postmarketing; Prospective Studies; Quinoxalines; Sleep Wake Disorders; Smoking Cessation; Surveys and Questionnaires; Varenicline; Young Adult | 2011 |
Treatment of nicotine dependence with Chantix (varenicline).
Topics: Adult; Benzazepines; Disclosure; Drug Interactions; Humans; Mental Disorders; Nausea; Nicotinic Agonists; Product Surveillance, Postmarketing; Quinoxalines; Randomized Controlled Trials as Topic; Risk Assessment; Safety; Smoking Cessation; Tobacco Use Disorder; Treatment Outcome; Varenicline; Young Adult | 2011 |
Neuropsychiatric events in varenicline and nicotine replacement patch users in the Military Health System.
Topics: Adult; Aged; Benzazepines; Bupropion; Female; Hospitalization; Humans; Male; Mental Disorders; Middle Aged; Military Personnel; Nicotinic Agonists; Quinoxalines; Retrospective Studies; Smoking Cessation; Tobacco Use Cessation Devices; United States; Varenicline; Young Adult | 2013 |
Low incidence of adverse events following varenicline initiation among opioid dependent smokers with comorbid psychiatric illness.
Topics: Benzazepines; Cardiovascular Diseases; Comorbidity; Data Interpretation, Statistical; Female; Humans; Longitudinal Studies; Male; Mental Disorders; Methadone; Middle Aged; Narcotics; Nicotinic Agonists; Opioid-Related Disorders; Prevalence; Primary Health Care; Quinoxalines; Smoking; Smoking Cessation; Socioeconomic Factors; Treatment Outcome; Varenicline | 2013 |
Efficacy of varenicline for smoking cessation.
Topics: Benzazepines; Humans; Mental Disorders; Quinoxalines; Smoking; Smoking Cessation; Varenicline | 2006 |
Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness.
Topics: Adult; Benzazepines; Cohort Studies; Drug Combinations; Female; Follow-Up Studies; Humans; London; Male; Mental Disorders; Middle Aged; Nicotine; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Substance Withdrawal Syndrome; Tobacco Use Disorder; Treatment Outcome; Varenicline | 2008 |
FDA warns of adverse events linked to smoking cessation drug and antiepileptics.
Topics: Anticonvulsants; Benzazepines; Humans; Mental Disorders; Quinoxalines; Risk; Smoking Cessation; Suicide; United States; United States Food and Drug Administration; Varenicline | 2008 |
Empowering dental hygienists: tobacco cessation resources.
Topics: Benzazepines; Dental Hygienists; Humans; Mental Disorders; Nicotinic Agonists; Product Surveillance, Postmarketing; Quinoxalines; Smoking Cessation; United States; United States Food and Drug Administration; Varenicline | 2008 |